Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial. (PubMed, Oncologist) - Oct 21, 2026 - P3 | "Vimseltinib continued to provide robust and durable antitumor activity and demonstrated long-term improvements in COAs, with manageable safety for the treatment of patients with TGCT not amenable to surgery."
Clinical • Clinical data • Journal • P3 data • Giant Cell Tumor of Bone • Hepatology • Liver Failure • Oncology • Solid Tumor • Tenosynovial Giant Cell Tumor • CSF1R
|
|
Albiruni Abdul Razak; Amanda Saunders; Andrew J Wagner; Antoine Italiano; Antonio Casado Herráez; Antonio López Pousa; Axel Le Cesne; Benjamin C Powers; Brooke Harrow; Christopher Tait; Emanuela Palmerini; Gabriel Tinoco; Giulia Agnello; Hans Gelderblom; Javier Martín-Broto; Jean-Yves Blay; Kjetil Boye; Mahbubl Ahmed; Maitreyi G Sharma; Matthew L Sherman; Michiel van de Sande; Nicholas M Bernthal; Peter Reichardt; Piotr Rutkowski; Salvatore Tafuto; Sarah Pratap; Sebastian Bauer; Silvia Stacchiotti; Vivek Bhadri; William D Tap
|